ALTAMIRA THERAPEUTICS (CYTOF) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 27, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-K for Q2 FY2025, filed Aug 29, 2025. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CYTOF SEC filings page.
This page shows ALTAMIRA THERAPEUTICS LTD (CYTOF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
ALTAMIRA THERAPEUTICS LTD does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
ALTAMIRA THERAPEUTICS LTD passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
ALTAMIRA THERAPEUTICS LTD reported a net loss of $8.5M while operations used $6.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
None of these metrics is reported for Q2 2025.
Cash & Balance Sheet
ALTAMIRA THERAPEUTICS LTD held $4K in cash as of Q2 2025; no long-term debt figure is on record for that period.
Not reported for Q2 2025.
Not reported for Q2 2025.
Margins & Returns
None of these metrics is reported for Q2 2025.
Capital Allocation
None of these metrics is reported for Q2 2025.
CYTOF Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA, Interest Expense, Income Tax, Net Income, EPS (Basic), EPS (Diluted), Diluted Shares (Avg).
CYTOF Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2510-K | Q4'2410-K | Q2'2410-Q | Q4'2310-K | Q4'2210-K |
|---|---|---|---|---|---|
| Total Assets | $7.1M-11.6% | $8.7M-5.4% | $8.1M | $9.1M+34.2% | $6.8M |
| Current Assets | $248K-52.8% | $1.5M+6.0% | $524K | $1.5M-24.0% | $1.9M |
| Cash & Equivalents | $4K-94.3% | $999K+36.1% | $65K | $734K+4309.0% | $17K |
| Inventory | N/A | N/A | N/A | N/A | $13K |
| Accounts Receivable | N/A | N/A | N/A | N/A | $7K |
| Total Liabilities | $3.1M+74.6% | $2.1M+42.1% | $1.8M | $1.5M-90.7% | $15.8M |
| Current Liabilities | $2.3M+88.1% | $1.2M+10.2% | $1.2M | $1.1M-92.4% | $13.9M |
| Non-Current Liabilities | $747K+42.8% | $923K+124.0% | $523K | $412K-78.1% | $1.9M |
| Total Equity | $4.1M-35.5% | $6.6M-14.5% | $6.3M | $7.7Mn/m | -$8.3M |
| Retained Earnings | -$4.0M-421.2% | -$3.0Mn/m | $1.3M | -$21.3Mn/m | -$226.3M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments, Goodwill, Long-Term Debt.
CYTOF Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Operating Cash Flow, Depreciation & Amortization, Stock-Based Compensation, Capital Expenditures, Free Cash Flow, Investing Cash Flow, Financing Cash Flow, Dividends Paid, Share Buybacks.
CYTOF Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Return on Equity, Return on Assets, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| ALTAMIRA THERAPEUTICS LTD CYTOF | FY2024 | N/A | -$8.5M | N/A | $572K | — |
| VINCERX PHARMA INC VINC | FY2024 | N/A | -$30.1M | N/A | N/A | — |
Where ALTAMIRA THERAPEUTICS LTD Ranks
Frequently Asked Questions
Is ALTAMIRA THERAPEUTICS LTD profitable?
No, ALTAMIRA THERAPEUTICS LTD (CYTOF) reported a net loss of $8.5M in fiscal year 2024.
What is ALTAMIRA THERAPEUTICS LTD's return on equity (ROE)?
ALTAMIRA THERAPEUTICS LTD (CYTOF) has a return on equity of -128.8% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.
What is ALTAMIRA THERAPEUTICS LTD's free cash flow?
ALTAMIRA THERAPEUTICS LTD (CYTOF) recorded an outflow of $6.2M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ALTAMIRA THERAPEUTICS LTD's operating cash flow?
ALTAMIRA THERAPEUTICS LTD (CYTOF) recorded an outflow of $6.1M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are ALTAMIRA THERAPEUTICS LTD's total assets?
ALTAMIRA THERAPEUTICS LTD (CYTOF) had $8.7M in total assets as of fiscal year 2024, including both current and long-term assets.
What are ALTAMIRA THERAPEUTICS LTD's capital expenditures?
ALTAMIRA THERAPEUTICS LTD (CYTOF) invested $103K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does ALTAMIRA THERAPEUTICS LTD spend on research and development?
ALTAMIRA THERAPEUTICS LTD (CYTOF) invested $3.7M in research and development during fiscal year 2024.
What is ALTAMIRA THERAPEUTICS LTD's current ratio?
ALTAMIRA THERAPEUTICS LTD (CYTOF) had a current ratio of 1.32 as of fiscal year 2024, which is considered adequate.
What is ALTAMIRA THERAPEUTICS LTD's liabilities-to-equity ratio?
ALTAMIRA THERAPEUTICS LTD (CYTOF) had a liabilities-to-equity ratio of 0.32 as of fiscal year 2024, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2024, because the filing data we hold for that year carries no long-term debt figure.
What is ALTAMIRA THERAPEUTICS LTD's return on assets (ROA)?
ALTAMIRA THERAPEUTICS LTD (CYTOF) had a return on assets of -97.8% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
What is ALTAMIRA THERAPEUTICS LTD's P/E ratio?
ALTAMIRA THERAPEUTICS LTD (CYTOF) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2024). The market capitalization is $572K as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ALTAMIRA THERAPEUTICS LTD's price-to-sales ratio?
ALTAMIRA THERAPEUTICS LTD (CYTOF) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $572K as of Oct 27, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is ALTAMIRA THERAPEUTICS LTD's Piotroski F-Score?
ALTAMIRA THERAPEUTICS LTD (CYTOF) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ALTAMIRA THERAPEUTICS LTD's earnings high quality?
ALTAMIRA THERAPEUTICS LTD (CYTOF) reported a net loss of $8.5M while operations used $6.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.